Abstracts tagged "IL-17A"

Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
Abstract Number: 1010 • 2019 ACR/ARP Annual Meeting
IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Tobias Russell¹, Abdulla Watad ², Charlie Bridgewood ³, Almas Khan ⁴, Abhay S Rao ⁴, Peter Loughenbury ⁴, Peter Milner ⁴, Robert Dunsmuir ⁴, Thomas Baboolal ³, Elena Jones ⁵, Richard Cuthbert ¹ and Dennis McGonagle ⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, England, United Kingdom, ²Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) is associated with entheseal inflammation and new bone formation. Resident populations of lymphocytes have been identified at the enthesis that on…
Abstract Number: 1553 • 2019 ACR/ARP Annual Meeting
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Philip Mease¹, Atul Deodhar ², Renato Calheiros ³, Xiangyi Meng ³, Todd Fox ⁴ and Xenofon Baraliakos ⁵, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: AS is a chronic, inflammatory disease of the axial skeleton associated with pain, stiffness, disability, and reduced quality of life (QOL).1 AS is defined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].